Cowen starts Profound Medical at OP; PT $15 (U.S.)

Profound Medical

Cowen launched coverage of Profound Medical (NASDAQ:PROF; TSX:PRN) with an “outperform” rating and $15 (U.S.) price target. The stock closed at $9.74 on March 31.

“[Profound’s] TULSA-PRO is a proprietary platform that offers an efficacious, incision-free alternative treatment option for prostate cancer and benign prostatic hyperplasia (BPH),” a non-cancerous enlargement of the prostate gland, writes analyst Dr. Joshua Jennings.

“We think TULSA-PRO will see solid near-term demand from cash-pay patients and then experience a longer-term inflection driven by reimbursement coverage,” he added. “Importantly, we do not expect COVID-19 to disrupt Profound’s traction this year.”

Dr. Jennings said TULSA-PRO’s technology advantages include being the only available treatment that utilizes a transurethral approach with thermal ablation; real-time thermal imaging capabilities provide physicians with live feedback to avoid overheating or underheating the prostate; and the ability to treat prostates of varying sizes, including larger prostates other platforms cannot treat.

“In our view, competitive platforms cannot match the versatility and flexibility of TULSA-PRO, which provides treatment options, ranging from whole gland ablation, to hemi-gland and even focal therapy,” he added.

In addition, he said TULSA-PRO’s MR-guided contouring capability allows physicians to preserve the neurovascular bundles near the prostate, which contributes to the procedure’s low adverse event rates.

Dr. Jennings also said TULSA-PRO’s U.S. rollout is gaining traction in leading academic hospitals, imaging centers and specialty urology practices focused on emerging technology. Profound is using a capital placement strategy in high-volume accounts, which seeds an attractive recurring revenue stream, while also selling TULSA-PRO to select U.S. customers and most accounts outside the U.S., he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.